Drug Profile
Research programme: immunotherapies - ImmunoCellular Therapeutics
Alternative Names: dendritic cell immunotherapies - Immunocellular therapeutics; Notch and numb pathway immunotherapies - ImmunoCellular TherapeuticsLatest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator ImmunoCellular Therapeutics
- Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines; Stem cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 13 Dec 2017 Research programme: immunotherapies - ImmunoCellular Therapeutics is available for licensing as of 13 Dec 2017. http://www.imuc.com/
- 09 Aug 2016 Preclinical development is on-going for Solid-tumours in USA (Parenteral)